Clinical trial
A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
NCT06985368 is registered in ClinicalTrials.gov with Shanghai Institute Of Biological Products as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
- Lead sponsor
- Shanghai Institute Of Biological Products
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- June 16, 2025
- Completion date
- September 15, 2028
- Enrollment
- 156 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor malignancy